| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CD246; NBLST3 |
| Entrez GeneID | 238 |
| clone | 8E8D3 |
| WB Predicted band size | 176kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human ALK (AA: 1366-1468) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇与ALK抗体相关的重要文献概览：
1. **《Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer》**
*作者：Soda M, et al. (2007), Nature*
摘要：首次在非小细胞肺癌中发现EML4-ALK融合基因，证实ALK基因重排驱动肿瘤发生，为ALK抗体检测及靶向治疗奠定基础。
2. **《Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer》**
*作者：Kwak EL, et al. (2010), New England Journal of Medicine*
摘要：报道ALK抑制剂克唑替尼(Crizotinib)在ALK阳性肺癌患者中的Ⅰ期临床试验，证明靶向ALK的抗体检测对患者分层治疗至关重要。
3. **《ALK antibodies in the diagnosis of ALK-rearranged lung adenocarcinomas: A comparative study of immunohistochemistry using different clones》**
*作者：Haller F, et al. (2015), Modern Pathology*
摘要：比较多种ALK抗体克隆(如D5F3、5A4)的敏感性和特异性，优化肺癌中ALK融合蛋白的免疫组化检测标准。
4. **《Oncogenic mutations of ALK in neuroblastoma》**
*作者：Mosse YP, et al. (2008), Nature*
摘要：揭示ALK基因激酶区突变在儿童神经母细胞瘤中的致癌作用，强调ALK抗体在突变蛋白检测及靶向治疗中的价值。
注：文献标题保留英文以方便检索，摘要内容为简化概括。如需具体文献链接或补充，可进一步说明。
ALK (anaplastic lymphoma kinase) antibodies are immunological tools targeting the ALK protein, a receptor tyrosine kinase encoded by the *ALK* gene. Initially identified in 1994 through its involvement in anaplastic large cell lymphoma (ALCL) via chromosomal translocation (t(2;5)), ALK gained prominence as an oncogenic driver. Aberrant ALK activation—through gene fusions (e.g., *EML4-ALK* in NSCLC), mutations, or amplifications—promotes cell proliferation and survival via downstream signaling pathways like RAS/MAPK and PI3K/AKT.
ALK antibodies are pivotal in diagnostics (e.g., immunohistochemistry, IHC) to detect ALK expression or fusion proteins in tumors, guiding targeted therapy eligibility. Therapeutically, monoclonal antibodies (mAbs) against ALK remain under exploration, though small-molecule inhibitors (e.g., crizotinib, alectinib) dominate clinical use. Research also focuses on ALK antibody-drug conjugates (ADCs) and bispecific antibodies to enhance specificity and overcome resistance.
Challenges include tumor heterogeneity, ALK variant diversity, and acquired resistance mutations (e.g., L1196M). Recent studies explore combinatorial approaches with immune checkpoint inhibitors or novel ALK-specific mAbs to improve outcomes. ALK antibodies thus bridge diagnostic precision and therapeutic innovation in ALK-driven cancers.
×
